ATENOLOL LACTATION STUDY

阿替洛尔哺乳期研究

• 批准号: 7603464
• 负责人: MARY F HEBERT
• 金额: $ 0.17万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603464
• 关键词: Academy; Adverse effects; American; Atenolol; Bradycardia; Breast Feeding; Computer Retrieval of Information on Scientific Projects Database; Condition; Discipline of Nursing; Drug Kinetics; Exclusive Breastfeeding; Exercise; Funding; Grant; Health Benefit; High Blood Pressure; Human; Human Milk; Hypertension; Impaired Renal Function; Infant; Institution; Lactation; Life; Pediatrics; Plasma; Postpartum Period; Pregnancy; Pregnant Women; Premature Infant; Product Labeling; Reporting; Research; Research Personnel; Resources; Source; Therapeutic; United States National Institutes of Health; Urine; Week; Woman; World Health Organization; clinically significant; design

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. High blood pressure is a common condition in pregnant women. Atenolol is an effective agent for the management of high blood pressure during and after pregnancy. We recently completed a study evaluating the pharmacokinetics of atenolol in pregnancy. However, no one has studied the pharmacokinetics of atenolol postpartum. Product labeling for atenolol states that "Atenolol is excreted in human breast milk at a ratio of 1.5 to 6.8 when compared to the concentration in plasma. Caution should be exercised when atenolol is administered to a nursing woman. Clinically significant bradycardia has been reported in breast fed infants. Premature infants, or infants with impaired renal function, may be more likely to develop adverse effects." Despite this warning, many women receiving atenolol for hypertension decide to breastfeed their infants. Because of the multiple health benefits for infants, exclusive breastfeeding for the first 6 months of life is recommended by the American Academy of Pediatrics and the World Health Organization. This study is designed to evaluate the pharmacokinetics of atenolol in plasma, urine and breast milk 2-4 weeks, 3-4 months and 6-8 months postpartum in women taking atenolol for therapeutic reasons and nursing their infants.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 高血压是孕妇的常见疾病。 阿替洛尔是一种有效的药物，用于管理高血压在怀孕期间和之后。 我们最近完成了一项研究，评价阿替洛尔在妊娠期的药代动力学。 然而，还没有人研究产后阿替洛尔的药代动力学。阿替洛尔的产品标签指出：“与血浆中的浓度相比，阿替洛尔以1.5 - 6.8的比例排泄到人母乳中。 哺乳期妇女使用阿替洛尔时应谨慎。 母乳喂养的婴儿曾报告过具有临床意义的心动过缓。 早产儿或肾功能受损的婴儿可能更容易出现不良反应。“尽管有这样的警告，许多接受阿替洛尔治疗高血压的妇女还是决定母乳喂养婴儿。 由于对婴儿的多种健康益处，美国儿科学会和世界卫生组织建议在生命的前6个月进行纯母乳喂养。 本研究旨在评价因治疗原因服用阿替洛尔并哺乳其婴儿的女性在产后2-4周、3-4个月和6-8个月时血浆、尿液和母乳中阿替洛尔的药代动力学。